nach oben

Current Infectious Disease Reports

Erschienen in:

01.01.2010

Non–AIDS-Defining Malignancies in Patients with HIV in the HAART Era

verfasst von: Minh Ly Nguyen, Kevin James Farrell, Clifford James Gunthel

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non–AIDS-related diseases. Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non–AIDS-defining malignancies (NADM). We review the causes underlying the rise in incidence of NADM and the clinical presentation, pathology, and treatment outcomes of the four most commonly encountered NADM in the HAART era. Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer. Among the non-infection-related cancers, lung and skin cancers predominate. The overall effect of HAART on NADM is unsettled. As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

Silverberg MJ, Chao C, Leyden WA, et al.: HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009, 23:2337–2345.CrossRefPubMed

Engels EA, Biggar RJ, Hall HI, et al.: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187–194.CrossRefPubMed

Stebbing J, Duru O, Bower M: Non–AIDS-defining cancers. Curr Opin Infect Dis 2009, 22:7–10.CrossRefPubMed

Engels EA, Pfeiffer RM, Goedert JJ, et al.; HIV/AIDS Cancer Match Study: trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20:1645–1654.CrossRefPubMed

• Shiels MS, Cole SR, Kirk GD, Poole C: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009, Epub ahead of print. This article provides a meta-analysis of 18 published population studies of cancer incidence data of people with HIV/AIDS, assessing effect of gender, AIDS, and the HAART era. Increased risk of NADM associated with infection and smoking, with certain cancer risk increased with immunosuppression.

Clifford G, Franceschi S: Immunity, infection, and cancer. Lancet 2007, 370:6–7.CrossRefPubMed

Frisch M, Biggar RJ, Engels EA, et al.; AIDS-Cancer Match Registry Study Group: Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001, 285:1736–1745.CrossRefPubMed

Mbulaiteye SM, Biggar RJ, Goedert JJ, et al.: Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003, 32:527–533.CrossRefPubMed

Patel P, Hanson DL, Sullivan PS, et al.; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008, 148:728–736.PubMed

10.

Powles T, Robinson D, Stebbing J, et al.: Highly active antiretroviral therapy and the incidence of non–AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009, 27:884–890.CrossRefPubMed

11.

• Baker JV, Peng G, Rapkin J,et al.: Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4⁺ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008, 22:841–848. This article describes a prospective study of the association between latest CD4 cell count and risk of AIDS and non-AIDS diseases in a cohort followed for a median of 5 years. Risk of non-AIDS cancer was significantly higher in those with lower CD4 cell counts.CrossRefPubMed

12.

• Bruyand M, Thiébaut R, Lawson-Ayayi S, et al.; Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA): Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009, 49:1109–1116. This article describes the first systematic study that points to an important role for CD4 ⁺ cell counts in increasing the risk of non-AIDS-associated malignancies.CrossRefPubMed

13.

• Grulich AE, van Leeuwen MT, Falster MO, et al.: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59–67. This article describes a meta-analysis of the published population cancer incidence rates of solid organ recipients and people with HIV/AIDS. The study identified a remarkably similar pattern of cancer occurrence in the two immunosuppressed populations.CrossRefPubMed

14.

Bouvard V, Baan R, Straif K, et al.; WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens—Part B: biological agents. Lancet Oncol 2009, 10:321–322.CrossRefPubMed

15.

Engels EA: Non–AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009, 23:875–885.CrossRefPubMed

16.

Biggar RJ, Kirby KA, Atkinson J, et al.; for the AIDS Cancer Match Study Group: Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004, 36:861–868.CrossRefPubMed

17.

Burgi A, Brodine S, Wegner S, et al.: Incidence and risk factors for the occurrence of non–AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005, 104:1505–1511.CrossRefPubMed

18.

Crum-Cianflone N, Hullsiek KH, Marconi V, et al.: Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009, 23:41–50.CrossRefPubMed

19.

Derhovanessian E, Solana R, Larbi A, Pawelec G: Immunity, ageing and cancer. Immun Ageing 2008, 5:11.CrossRefPubMed

20.

Appay V, Almeida JR, Dauce D, et al.: Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007, 42:432–437.CrossRefPubMed

21.

Hessol NA, Pipkin S, Schwarcz S, et al.: The impact of highly active antiretroviral therapy on non–AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007, 165:1143–1153.CrossRefPubMed

22.

Silverberg MJ, Neuhaus J, Bower M, et al.: Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007, 21:1957–1963.CrossRefPubMed

23.

Clifford GM, Polesel J, Rickenbach M, et al.: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97:425–432.PubMedCrossRef

24.

Crum-Cianflone NF, Hullsiek KH, Marconi V, et al.: The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2009, 51:305–9.CrossRefPubMed

25.

Vidrive DJ: Cigarette smoking and HIV/AIDS: health implications, smoker characteristics and cessation strategies. AIDS Educ Prev 2009, 2(13 Suppl):3–13.CrossRef

26.

Guech-Ongey M, Engels EA, Goedert JJ, et al.: Elevated risk for squamous cell carcinoma of the conjunctiva among adults with AIDS in the United States. Int J Cancer 2008, 122:2590–2593.CrossRefPubMed

27.

Crum-Cianflone N, Hullsiek KH, Satter E, et al.: Cutaneous malignancies among HIV-infected persons. Arch Intern Med 2009, 169:1130–1138.CrossRefPubMed

28.

Engels EA, Brock MV, Chen J et al.: Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006, 24:1383–1388.CrossRefPubMed

29.

• Kirk GD, Merlo C, O’ Driscoll P, et al.: HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007, 45:103–110. This article describes the first study to show an association between HIV infection and lung cancer risk, independent of smoking history.CrossRefPubMed

30.

Yu YY, Pinsky PF, Caporaso NE, et al.: Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med 2008, 168:2326–2332.CrossRefPubMed

31.

Brock MV, Hooker CM, Engels EA, et al.: Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006, 43:47–55.CrossRefPubMed

32.

Lavolé A, Wislez M, Antoine M, et al.: Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006, 51:1–11.CrossRefPubMed

33.

Lavolé A, Chouaïd C, Baudrin L, et al.: Effect of highly active antiretroviral therapy on survival of HIV infected patients with Non–small-cell lung cancer. Lung Cancer 2009, 65:345–350.CrossRefPubMed

34.

Biggar RJ, Jaffe ES, Goedert JJ, et al.: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006, 108:3786–3791.CrossRefPubMed

35.

Engels EA, Pfeiffer RM, Goedert JJ, et al.; HIV/AIDS Cancer Match Study: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. AIDS 2006, 20:1645–1654.CrossRefPubMed

36.

Carbone A, Gloghini A, Serraino D, Spina M: HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009, 4:3–10.CrossRefPubMed

37.

Rezk SA, Weiss LM: Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007, 38:1293–1304.CrossRefPubMed

38.

Gérard L, Galicier L, Boulanger E, et al.: Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003, 17:81–87.CrossRefPubMed

39.

Spina M, Gabarre J, Rossi G, et al.: Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002, 100:1984–1988.CrossRefPubMed

40.

Xicoy B, Ribera JM, Romeu J, et al.: Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin’s lymphoma. Leuk Lymphoma 2007, 48:2058–2059.CrossRefPubMed

41.

Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101:1120–1130.CrossRefPubMed

42.

Palefsky JM, Rubin M: The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am 2009, 36:187–200.CrossRefPubMed

43.

Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy. Oncol Rep 2007, 17:1121–1126.PubMed

44.

Palefsky JM, Holly EA, Efirdc JT et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005, 19:1407–1414.CrossRefPubMed

45.

Bower M, Powles T, Newsom-Davis T, et al.: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004, 37:1563–1565.CrossRefPubMed

46.

Association of Reproductive Health Professionals: Managing HPV: a new era in patient care. Available at http://www.arhp.org/publications-and-resources/clinical-proceedings/Managing-HPV/Cytology. Accessed September 2009.

47.

Pineda CE, Berry JM, Jay N, et al.: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008, 51:829–835.CrossRefPubMed

48.

Place RJ, Gregorcyk SG, Huber PJ, et al.: Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum 2001, 44:506–512.CrossRefPubMed

49.

Clifford GM, Rickenbach M, Polesel J, et al.; Swiss HIV Cohort: Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008, 22:2135–2141.CrossRefPubMed

50.

Puoti M, Bruno R, Soriano V, et al.; HIV HCC Cooperative Italian-Spanish Group: Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004, 18:2285–2293.CrossRefPubMed

51.

Bräu N, Fox RK, Xiao P, Marks K et al.; North American Liver Cancer in HIV Study Group: Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007, 47:527–537.CrossRefPubMed

52.

Di Benedetto F, Di Sandro S, De Ruvo N, et al.: Human immunodeficiency virus and liver transplantation: our point of view. Transplant Proc 2008, 40:1965–1971.CrossRefPubMed

53.

US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008; 1–139. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed August 2009.

54.

• Osborn M: Hepatitis B in HIV: available treatment options and approach to therapy. Curr Infect Dis Rep 2009, 11:407–413. This article provides a comprehensive review of treatment of HBV in HIV-coinfected patients.CrossRefPubMed

Titel: Non–AIDS-Defining Malignancies in Patients with HIV in the HAART Era
verfasst von: Minh Ly Nguyen
Kevin James Farrell
Clifford James Gunthel
Publikationsdatum: 01.01.2010
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 1/2010
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-009-0075-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Non–AIDS-Defining Malignancies in Patients with HIV in the HAART Era

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Current Views on the Clinical Relevance of Blastocystis spp.

Renal Transplantation in HIV-Positive Recipients

Advances in the Development of Microbicides for the Prevention of HIV Infection

Drug-Resistant Tuberculosis in Sub-Saharan Africa

Antimicrobial Therapy of Otitis Media Reduces the Incidence of Mastoiditis

The HIV-Infected Adolescent

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Innere Medizin